Introduction
============

The malaria-causing parasite *Plasmodium falciparum* utilizes multiple molecular pathways for invasion of human erythrocytes ([@bib8]). Underlying these diverse methods of entry is the ability of parasites to bind to the cell via numerous receptor--ligand interactions ([@bib1]). Several distinct molecules comprise the human ligands targeted during invasion, including Glycophorins A, B, and C (encoded by *GYPA*, *GYPB*, and *GYPC*, respectively), as well as other unidentified players ([@bib5]). Elucidating the molecular evolution of these molecules is critical to understanding the historical coevolutionary interactions between humans and *P. falciparum* and the origins of human alleles that provide resistance to malarial disease.

In a comparison of 280 human gene sequences with their orthologs in Old World monkeys, [@bib37] identified *GYPA*,*GYPB*, and *GYPE* (the latter encodes Glycophorin E, which currently has no known role in erythrocyte invasion by *Plasmodium*) as having among the highest rates of nonsynonymous evolution. These genes share significant homology and likely arose through duplication events in the primate lineage ([@bib30]; [@bib25]; [@bib37]). The high rate of evolution of the glycophorins has been explained by two competing hypotheses. In their examination of *GYPA*, [@bib2] proposed the "decoy" hypothesis, whereby the extracellular components of erythrocytic sialoglycoproteins bind with and sequester nonerythrocytic intracellular pathogens (e.g., bacteria and viruses), thereby preventing their invasion of nucleated cells. [@bib2] suggest that species-specific pathogen pressures result in high rates of nonsynonymous divergence between species and maintenance of high levels of polymorphism within species. [@bib37] offer an alternative "evasion" hypothesis that proposes that the rapid evolution of glycophorins is in response to *Plasmodium* pathogens that recognize these molecules for entry into the erythrocyte. Coevolution between *Plasmodium* receptors and their glycophorin ligands on the human erythrocyte is proposed to drive the rapid evolution of glycophorin-encoding genes. The observation that segregating variants at *P. falciparum* genes encoding erythrocyte receptors have dramatically different sialoglycoprotein-binding specificities provides support for the evasion hypothesis ([@bib20], [@bib21]).

To date, analyses of the molecular evolution and population genetics of sialoglycoprotein-encoding genes have largely ignored *GYPC*. In part, this may be because the gene did not emerge as one of the very rapidly evolving loci identified in the [@bib37] survey. *GYPC* is unique among the glycophorin genes in two respects: First, its sequence is not homologous to any other gene, whereas *GYPA*, *GYPB*, and *GYPE* are all paralogous. Second, *GYPC* encodes two distinct sialoglycoproteins, Glycophorin C (GPC) and Glycophorin D (GPD), through initiation of translation at two separate start sites within a single mRNA transcript, as shown in [figure 1](#fig1){ref-type="fig"} ([@bib36]; [@bib15]). Only GPC is known to play a role in erythrocyte invasion by *P. falciparum*; this interaction is mediated through the parasite\'s EBA140 (BAEBL) receptor ([@bib17]). This distinction between GPC and GPD with respect to EBA140 binding likely is due to an N-linked glycan that modifies GPC (but not GPD) and is necessary for receptor recognition ([@bib19]).

![Structure of human *GYPC*. The proteins GPC and GPD are encoded via initiation of translation at separate start codons in exons 1 and 2, respectively (coding exons are indicated by tall boxes, untranslated region by short boxes, and introns by lines). The gene is drawn to scale, except that exons 1 and 2 are separated by an intron that is approximately 34 kb in length.](molbiolevolmsp183f01_lw){#fig1}

*GYPC* is also of interest because an allele encoding a structural variant segregates at high frequencies among Melanesians and is responsible for the Gerbich-negative (Ge−) phenotype ([@bib3]). This allele contains a large deletion that eliminates the third exon of the gene and thereby affects the extracellular components of both GPC and GPD ([@bib33]). Ge− is common enough to result in large numbers of homozygous individuals in affected populations; these individuals often exhibit erythrocyte ovalocytosis with no clinical symptoms ([@bib27], [@bib26]). Importantly, *P. falciparum* EBA140 does not bind to Ge− cells, indicating that features of the peptide sequence in the deleted region are critical for parasite recognition ([@bib20], [@bib19]; [@bib17]). [@bib19] suggest that interactions between the peptide backbone and an N-linked glycan may be critical for proper exposure of the ligand recognized by EBA140. From an evolutionary perspective, the failure of EBA140 to bind with Ge− cells suggests that the Ge− phenotype may be maintained in populations through malaria selection.

Our study examines the molecular evolution of *GYPC* in the Hominoidea, as well as patterns of polymorphism within human populations. Our goal is to test whether an elevated rate of amino acid evolution exists at this gene. If so, we will investigate whether this signature is restricted to the human linage (consistent with recent adaptive evolution mediated by *P. falciparum* or another species-specific parasite) and/or restricted to extracellular regions of the protein (where interactions with *P. falciparum* or other parasites might occur). By examining human polymorphism in a global diversity panel, we will test whether there is a signature of recent natural selection at the *GYPC* locus (either in the form of positive selection increasing the frequency of a single allele or diversity-maintaining selection favoring the presence of many alleles).

Materials and Methods
=====================

Biological Materials
--------------------

Nonhuman primate DNA samples were obtained from the Integrated Primate Biomaterials Resource. These included samples from five species: common chimpanzee (*Pan troglodytes*), bonobo (*Pan paniscus*), gorilla (*Gorilla gorilla*), orangutan (*Pongo pygmaeus*), and white-cheeked gibbon (*Nomascus leucogenys*). In addition, DNA from 50 human individuals, representing a global sample of diversity (including 20 sub-Saharan Africans, 10 Europeans, 5 Middle Easterners, 10 Asians, 3 Oceanians, and 2 Native Americans) was obtained from the Coriell Cell Repository; specific sample identities are detailed in [Supplementary Material](http://mbe.oxfordjournals.org/cgi/content/full/msp183/DC1) online. A whole-blood sample from a single *P. troglodytes* individual was obtained from the Yerkes Primate Center. Whole-blood from a single human sample was obtained via venipuncture from a single subject. Human blood collection was obtained with prior informed consent and all human-subject protocols were approved by appropriate institutional review boards.

DNA Sequencing
--------------

We sequenced the nucleotide region encompassing the entire protein-coding segment of *GYPC* in all human and nonhuman samples (adjacent intron sequence was also examined for polymorphism in our human samples, as described in Results). Diploid sequence data were produced by direct sequencing of amplicons with overlapping primers on both strands. Primers used for amplification and sequencing are available from the authors on request. Sequences were assembled and variable sites identified using the program Sequencher v. 4.7 (GeneCodes).

Western Blotting
----------------

To investigate the protein products encoded by *GYPC* in humans and *P. troglodytes*, we used an immunoblotting procedure to stain GPC and GPD. We sampled 15 ml of whole heparinized blood from a single human and chimpanzee and prepared erythrocyte ghosts using a cell lysis procedure ([@bib32]; [@bib10]). Diluted membranes were run on a 15% Tris--glycine sodium dodecyl sulfate polyacrylamide gel, transferred to a nitrocellulose membrane, and treated with a 1:1,000 dilution of primary antibody. This antibody was monoclonal mouse antihuman CD236 (AbD Serotec), which recognizes a 17 amino acid motif in the fourth exon of *GYPC* ([@bib13]). This motif is shared by GPC and GPD and is completely conserved between our human and *P. troglodytes* samples (as determined via DNA sequencing, data not shown). After primary incubation, the blot was treated with a 1:2,500 dilution of secondary antibody, rabbit F(ab′)2 antimouse IgG:HRP (AbD Serotec) and visualized using a GE Healthcare immunodetection kit.

DNA Sequence Analyses
---------------------

### PAML Analyses

We used the program "codeml" in the software package Phylogenetic Analysis by Maximum Likelihood v. 4.2a (PAML; [@bib40]) to fit models of sequence evolution to our Hominoidea data set (*GYPC* sequence from all five nonhuman primates, plus a single human sequence). This procedure requires specification of a phylogenetic tree. In our analyses, we implemented a standard unrooted Hominoidea phylogeny, shown in [figure 2*A*](#fig2){ref-type="fig"}. Initial branch lengths were estimated for this tree using PAML model 0 (M0), which estimates a single ratio of nonsynonymous to synonymous evolution (the *d*~N~/*d*~S~ ratio, or *ω*) that applies to all sites in all taxa.

![(*A*) Translation initiation regions of GPC and GPD. The GPC start codon (boxed) is present only in humans, whereas the GPD start codon is conserved across all Apes. Starred sites denote loci important for efficient recognition of the start codon by the ribosome; translation is typically most efficient when there is a purine at position −3 (which is true for GPC and GPD), and a G at position +1 (which is true only for GPD). (*B*) Western blotting of *GYPC* products in human and chimpanzee. Using an antibody recognizing an epitope shared by GPC and GPD, and exactly conserved between humans and chimpanzee, we detect both proteins in human erythrocyte ghosts (Hs) but only GPD in chimpanzee (Pt).](molbiolevolmsp183f02_ht){#fig2}

To test for positive selection using PAML, we used two separate classes of evolutionary models. The first class includes the "site models," where codon sites are allowed to fall into categories that differ with respect to their *ω* values. These values apply to all branches of the phylogeny. The second class of models are the "branch-site" models, which are similar to the site models in that different codons, can have different *ω* values; however, the phylogeny is split into "foreground" and "background" branches that contain categories of sites with different *ω* values. Of the site models, we examined several, which differ in the number of classes of sites, to test for positive selection. First, we compared the likelihood values associated with a "Nearly Neutral" model (M1a) and a "Positive Selection" model (M2a), originally described in [@bib39]. Briefly, M1a assumes all codon sites fall into two classes, *ω*~1~ and *w*~0~, with a single value of *ω* describing each class (equal to 1 in the former, and free to vary below 1 in the latter). Model M2a adds an additional site class that is free to vary above one. In both models, the proportion of sites falling into each class is free to vary. The likelihood values associated with the data under the two models were compared using likelihood ratio tests, as described in [@bib41]. In addition to M1a and M2a, we examined several additional site models, M7, M8, and M8a. Model M7 is similar to model M1a except that the sites affected by negative selection (*ω* \< 1) approximate a beta distribution with parameters (*p* and *q*) estimated from the data. M8 is related to M7 in the same way that M2a is related to M1a---an additional class of sites is added to M8 that is affected by positive selection (*ω* \> 1). Models M7 and M8 were initially described by [@bib41]. A final model, M8a, forms an alternative null model to compare with M8 ([@bib34]). Model M8a is identical to M8, but the *ω* value for the positively selected class is fixed at 1. Likelihood ratio tests were used to compare M8 with M8a and M7, as described by [@bib34] and [@bib39]. The posterior probabilities associated with specific codons falling into a site class affected by positive selection (in models M8 and M2a) was calculated using the Bayes empirical Bayes (BEB) method described by [@bib42]. These methods were applied to several different partitions of the data, as described in the Results section.

To examine whether humans are characterized by a different pattern of molecular evolution at *GYPC* compared with the rest of the Hominoidea, we used a pair of "branch-site models." In these models, the branch of the phylogeny leading to humans was classified as the foreground branch and all others as "background branches." We used the branch-site test of selection developed by [@bib44] to test for positive selection acting on a subset of sites in the human lineage. This test allows for two categories of sites affected by positive selection (*ω* \> 1) in the foreground, together with a category of sites affected by negative selection (*ω* \< 1) and a neutrally evolving class of sites (*ω* = 1). The background branches contain sites in only the latter two classes. Likelihood values associated with this model are estimated and compared with a null model in which both foreground and background branches contain only sites where *ω* ≤ 1. In the null model, foreground branches can have a higher fraction of neutrally evolving sites (*ω* = 1) than background branches, making this test of selection robust to a relaxation of constraints in the foreground branches. Likelihood values for the two models were compared as described in [@bib44]. As with the site models, maximum likelihood estimates of data parameters are generated from the data. Similarly, the method generates BEB posterior probabilities associated with particular sites falling into the positively selected class.

In all PAML analyses, codons containing alignment gaps due to insertion--deletion events among species were treated as missing data and not considered in pairwise comparisons where one species contained sequence and another species did not.

### Polymorphism Analyses

In our human polymorphism data set (2*n*=100), diploid sequence was arbitrarily phased and intron--exon boundaries annotated. We employed several measures of polymorphism and tests of neutrality using the program DNAsp v.4.50.3 ([@bib31]). These included two estimates of the population-mutation parameter (*θ*), including [@bib38] method (*θ*~W~), which is based on the number of segregating sites in a sample, and π, which is the average number of pairwise differences between sequences in a sample ([@bib23]). Tests of selection included three that examine the frequency spectrum of mutations, Tajima\'s (1989) *D* (TD), Fu and Li\'s (1993) *D* (FLD), and Fay and Wu\'s (2000) *H* (FWH). Significance of these tests was assessed via coalescent simulations, implemented in DNAsp. We also performed a [@bib22] test, which examines the numbers of synonymous and nonsynonymous substitutions between species and polymorphic sites within species. For all tests requiring outgroup information, data from a single *P. troglodytes* were used.

Results
=======

We sequenced the complete coding region of *GYPC* in six Hominoidea species. These data revealed that the translation start site associated with GPC is present in humans but not other taxa. This is due to a C to A transversion that created a novel translation start codon in humans. The translation start site used to encode GPD is well conserved among all taxa. Sequence data associated with the two start codons are shown in **[figure 2*A*](#fig2){ref-type="fig"}**. These data strongly suggest that only humans encode two protein products (GPC and GPD) at the *GYPC* gene. Western blotting of human and *P. troglodytes* erythrocyte ghosts confirms that the latter encodes only a single protein product of *GYPC*, conforming in size to GPD ([fig. 2*B*](#fig2){ref-type="fig"}).

Nonsynonymous and Synonymous Evolution
--------------------------------------

Because only humans have the ability to produce GPC, we define the shared coding region among taxa in our sample as only the portion of *GYPC* that encodes GPD. Limiting our analysis to this region, examination of nonsynonymous and synonymous evolution using PAML suggests that the gene has been subject to positive selection among the Hominoidea. Analyses of the entire gene (and including all six taxa) using site models suggest that models incorporating positive selection (M2a and M8) are significantly better fits to the data than models including only purifying selection and neutrally evolving sites (M1a, M7, and M8a); these results are shown in [table 1](#tbl1){ref-type="table"} (a multispecies alignment showing all data considered in PAML analyses is included in [supplementary figure 1](http://mbe.oxfordjournals.org/cgi/content/full/msp183/DC1), [Supplementary Material](http://mbe.oxfordjournals.org/cgi/content/full/msp183/DC1) online). When we remove from exon 3 our analysis, the portion of the gene that when deleted in humans confers resistance to malaria (the Ge− phenotype), we observe that models including positive selection no longer provide better fits to the data than nearly neutral models. Finally, when we remove humans from the data set and reperform our analysis on the full gene from the five remaining Hominoidea, we see that models incorporating positive selection are not better fits to the data than nearly neutral models. This implies that positive selection may be limited to only the human lineage. The results of the "branch-site" test bolster this inference. In this test, a model allowing positive selection in only the human lineage is a significantly better fit to the data than a model in which all branches of the phylogeny are allowed to evolve with *ω* ≤ 1 ([table 2](#tbl2){ref-type="table"}). The branch-site test of positive selection is not significant when any other single branch of the phylogeny is elevated to the foreground (data not shown).

###### 

PAML-Implemented Site Models of Positive Selection

  Model[a](#tblfn1){ref-type="table-fn"}   ln *L*      Parameter Estimates[b](#tblfn2){ref-type="table-fn"}                               Selected Codons[c](#tblfn3){ref-type="table-fn"}
  ---------------------------------------- ----------- ---------------------------------------------------------------------------------- --------------------------------------------------
  All species, full gene                                                                                                                  
      M1a                                  −679.00                                                                                        
      M2a                                  −673.02\*   *p*~0~ = 0.436 (*ω*~0~ = 0.032), *p*~1~ = 0.529, *p*~2~ = 0.035 (*ω*~2~ = 21.88)   24 (0.82), 27 (0.99), 36 (0.88)
      M7                                   −679.12                                                                                        
      M8A                                  −678.99                                                                                        
      M8                                   −673.06\*   *p*~0~ = 0.44 (*p* = 0.02, *q* = 0.01), *p*~2~ = 0.035 (*ω*~2~ = 21.39)            24 (0.85), 27 (0.99), 36 (0.91)
  All species, exon 3 excluded                                                                                                            
      M1a                                  −413.81     *p*~0~ = 0.876 (*ω*~0~ = 0.209), *p*~1~ = 0.124                                    
      M2a                                  −413.80                                                                                        
      M7                                   −413.71     *p* = 0.758, *q* = 1.756                                                           
      M8a                                  −413.71     *p*~0~ = 0.999 (*p* = 0.747, *q* = 1.725), *p*~1~ = 0.001                          
      M8                                   −413.71                                                                                        
  Human excluded, full gene                                                                                                               
      M1a                                  −619.31     *p*~0~ = 0.389 (*ω*~0~ = 0.0), *p*~1~ = 0.611                                      
      M2a                                  −618.26                                                                                        
      M7                                   −619.32     *p* = 0.008, *q* = 0.005                                                           
      M8a                                  −619.31     *p*~0~ = 0.389 (*p* = 0.005, *q* = 1.554), *p*~1~ = 0.611                          
      M8                                   −618.26                                                                                        

\**P* \< 0.05, comparing model including positive selection (M2a or M8) to nearly neutral model (M1a, M7, or M8a).

All models and comparisons among models are described in the text. Asterisks indicate comparisons where models that incorporate a class of sites affected by positive selection are better fits to the data than nearly neutral models (Models M2a and M8 in the "all species, full gene" comparison); in all other comparisons, models incorporating positive selection are not better fits to the data than nearly neutral models.

Parameter abbreviations are as follows: *p*~0~ = proportion of sites falling into nearly neutral site class (followed by estimate of *ω*~0~ for models M1a and M2a or shape parameters of the beta distribution (*p*,*q*) for models M7, M8a, and M8), *p*~1~ = proportion of sites falling into neutral site class (*ω*~1~ = 1); *p*~2~ = proportion of sites falling into positively selected site class (followed by estimate of *ω*~2~).

BEB estimates of sites falling into positively selected class are listed for those where the posterior probability (in parentheses) is greater than 0.8.

###### 

PAML-Implemented Branch-Site Tests of Positive Selection

  Model                                                       ln *L*      Parameter Estimates                                                                          Selected Codons
  ----------------------------------------------------------- ----------- -------------------------------------------------------------------------------------------- -----------------
  A~null~                                                     −679.00     Foreground: *p*~0~ = 0.458 (*ω*~0~ = 0.0), *p*~1~ = 0.542                                    
  Background: *p*~0~ = 0.458 (*ω*~0~ = 0.0), *p*~1~ = 0.542                                                                                                            
  A                                                           −673.08\*   Foreground: *p*~0~ = 0.415 (ω~0~ = 0.0), *p*~1~ = 0.573,*p*~2~ = 0.012 (*ω*~2~ = infinite)   27 (0.99)
  Background: *p*~0~ = 0.420 (*ω*~0~ = 0.0), *p*~1~ = 0.580                                                                                                            

N[OTE.]{.smallcaps}---Models are as discussed in text; parameters are as described in [table 1](#tbl1){ref-type="table"}. Foreground branch includes the branch leading to humans, background branches include all other branches of the Hominoidea phylogeny. On the foreground branch in Model A, two classes of selected sites (*ω* \> 1) are possible (as described in Materials and Methods); however, only one class is populated in the present analysis.

\**P* \< 0.05, comparing model A with A~null~.

[Tables 1](#tbl1){ref-type="table"} and [2](#tbl2){ref-type="table"} show that a relatively small proportion of sites within *GYPC* appear to be affected by positive selection. Analysis of the entire gene under the site model suggests 3.5% of codons are targeted by selection but that selection affecting this class of sites is quite strong (*ω* = 21.88). The branch-site models suggest an even smaller fraction of sites are targets of positive selection in the human lineage (1.2%) but that these sites are affected by very strong positive selection (a specific value of *ω* could not be estimated---a result that is likely affected by the small number of sites in the analysis). Results of the BEB analysis in both the site and branch-site models suggest that codons affected by positive selection all fall within the third exon of *GYPC* ([fig. 3](#fig3){ref-type="fig"}). In particular, all models provide strong support for the 27th codon falling into the selected site class (posterior probability \> 0.99); the site models (M2a and M8) provide moderate support for the 24th and 26th codons falling into this class (posterior probability \> 0.80).

![Putative selected codons within GYPC. The posterior probability of each codon having an *ω* \> 1 is shown for those with a probability \>0.5 (values taken from the BEB analysis performed under PAML model M2a for the full data set). Extracellular, transmembrane, and cytosolic regions of the encoded protein are shown. The dotted line shows the location of the exon 3 deletion, which segregates in human populations and is hypothesized to confer resistance to falciparum malaria; bases upstream of the dotted line fall within exon 2 and downstream bases fall within exon 4.](molbiolevolmsp183f03_ht){#fig3}

Polymorphism within Humans
--------------------------

To examine variation in a human sample, we resequenced 1,235 bp of *GYPC* from 50 individuals (2*n* = 100). This comprised the entire coding region of the gene (387 bp), plus noncoding DNA adjacent to each exon (exon 1 region: 50 bp 5′ untranslated region (UTR), 49 bp exon, 242 bp intron; exon 2 region: 57 bp exon, 218 bp intron; exon 3 region: 84 bp exon, 220 bp intron; exon 4: 197 bp exon, 118 bp 3′ UTR). Our survey uncovered nine segregating sites, all of which lie within or adjacent to exons 2, 3, and 4. Genotype data for the 50 samples are shown in accompanying [supplementary figure 2](http://mbe.oxfordjournals.org/cgi/content/full/msp183/DC1), [Supplementary Material](http://mbe.oxfordjournals.org/cgi/content/full/msp183/DC1) online. Of the nine sites that vary, one is a synonymous variant within the coding region, seven are polymorphisms in noncoding DNA, and one is a nonsynonymous polymorphism. A McDonald--Kreitman test revealed no significant deviations from expected patterns under neutrality (8 silent and 1 nonsynonymous polymorphic sites, 24 silent and 12 nonsynonymous substitutions; *P* = 0.249 by Fisher\'s Exact test). In contrast, one test of neutrality based on the frequency spectrum of mutations shows significant departures from standard neutral expectations ([table 3](#tbl3){ref-type="table"}). Specifically, Fay and Wu\'s *H* (= −3.79) describes an excess of high frequency--derived alleles in the data set; Tajima\'s *D* and Fu and Li\'s *D*, in contrast, do not deviate from expected patterns under neutrality. Significance values reported in [table 3](#tbl3){ref-type="table"} are taken from simulations of the coalescent process that do not incorporate recombination; these values are conservative relative to simulations conditioned on nonzero values of recombination.

###### 

Summary Statistics Describing Polymorphism at Human *GYPC*

  *S*          9        
  ------------ -------- -------------
  *θ*~W~ (%)   0.141    
  *π* (%)      0.096    
  TD           −0.792   *P* = 0.247
  FWH          −3.788   *P* = 0.015
  FLD          −1.749   *P* = 0.118

N[OTE.]{.smallcaps}---*P* values indicate probability of observing a smaller value based on neutral coalescent simulations.

Discussion
==========

*GYPC* is a rapidly evolving gene that has been subject to positive natural selection in the human lineage. Our data suggest that diversifying selection has caused rapid amino acid evolution in a portion of the gene (the third exon) that is likely to affect *Plasmodium* invasion of the red blood cell. Our data also reveal the unexpected result that humans have evolved a novel start codon upstream of the ancestral *GYPC* translation initiation site. This new start codon is fixed in our global human sample and allows humans to encode two proteins, GPC and GPD, from a single transcript. DNA sequence and protein immunoblotting data confirm that all other sampled Apes encode only GPD at this locus. Our data have important implications with respect to understanding the forces driving sialoglycoprotein evolution and the coevolutionary interactions between humans and malaria-causing parasites. Moreover, our data point to a novel evolutionary pathway by which protein innovation occurs.

Positive Selection at *GYPC*
----------------------------

*GYPC* sequence data from the Hominoidea indicate that the locus is subject to higher rates of amino acid evolution in the human lineage than expected under neutrality. When we examine the total data set from six species, we find that site models of DNA sequence evolution that include a class of positively selected codons are significantly better fits to the data than models that do not. This result is dependent on inclusion of humans in the sequence analysis, suggesting that positive selection may be restricted to just the branch of the Hominoidea phylogeny leading to humans. We have tested this hypothesis by performing a branch-site test of accelerated evolution on the human lineage. This test confirms that models of sequence evolution in which only human *GYPC* harbors a class of sites affected by positive selection are better fits to the data than models where all branches of the phylogeny are evolving under purifying selection and/or neutrality. Because the null model in this latter test allows for human *GYPC* to have sites characterized by higher (but ≤1) *ω* values than other branches of the phylogeny, this test confirms that human *GYPC* has experienced accelerated amino acid evolution due to positive selection, not a relaxation of selective constraints.

In both the site and branch-site models of *GYPC* sequence evolution, the principal target of positive selection appears to be regions of the gene encoding extracellular protein components ([fig. 3](#fig3){ref-type="fig"}). All sites identified through BEB analysis as candidate targets of positive selection fall within the third exon of the gene, corresponding to the region that is deleted in the malaria-resistant Ge− allele in humans. Exclusion of the third exon of the gene from our PAML analyses eliminates any suggestion in the data that *GYPC* has been subject to positive selection. This result indicates that only a small portion of the gene has been targeted by positive selection and that sequence encoding intramembrane and intracellular protein regions are evolving under the constraints of purifying selection and/or neutrality.

Complementing the long-term positive selection indicated by interspecies comparisons, our human *GYPC* polymorphism data suggest that a recent genetic hitchhiking event has affected the locus in *Homo sapiens*. Specifically, our data show an excess of polymorphic sites with high frequency--derived alleles (indicated by a significantly negative value of FWH) over neutral expectations. This pattern is consistent with a selected allele being driven to very high frequency at the locus in the relatively recent past. Our failure to observe significant skews in the allele frequency spectrum using TD and FLD does not contradict our interpretation of significant FWH values. Each of these tests has limited power to detect natural selection, and their sensitivity to different aspects of the data make them complementary ([@bib6]; [@bib28]). Analysis of our data using a McDonald--Kreitman test also reveals no departures from neutral expectations. This latter test can lack power to detect recent positive selection because silent and replacement sites tightly linked to a target of selection will experience a reduction in variation during a selective sweep ([@bib24]).

The interpretation of a high frequency of derived alleles in our polymorphism survey is complicated by the fact that we sampled humans sparsely from a large number of populations. The presence of population structure in polymorphism data can affect the site frequency spectrum ([@bib29]; [@bib9]). FWH, in particular, has been shown to be sensitive to population subdivision under an island model when demes are sampled unequally ([@bib28]; [@bib43]). Because of this, further surveys of polymorphism in individual populations will help to clarify the extent to which hitchhiking events have affected *GYPC.* If the observed skew in the site frequency is, in fact, caused by recent natural selection, then we predict that that the hitchhiking event must have occurred relatively recently because an excess of high frequency alleles is expected to be a highly transient signature of recent positive selection ([@bib11], [@bib12]; [@bib28]).

What Drives Positive Selection at *GYPC*?
-----------------------------------------

Our results suggest that *GYPC* has been a target of positive selection in humans over both short and long timeframes (i.e., recently enough to be evident in the pattern of polymorphism within humans and also over timescales long enough to result in an excess of amino acid substitutions between humans and related species). We propose that our data are broadly consistent with selection mediated by *P. falciparum* as predicted by the evasion hypothesis ([@bib37]). In the case of *GYPC,* selection for evasion has been limited to the human lineage and is coincident with the evolution of a new protein product (GPC) at the locus. Because there is no evidence that the ancestral *GYPC* protein product (GPD) interacts with *P. falciparum* it is likely that *GYPC* has been subject to malaria-related selection only since the GPC start codon evolved. Subsequent to this event, rapid evolution of extracellular amino acid residues encoded by *GYPC* may have occurred in the human lineage to mitigate erythrocyte invasion by *P. falciparum*. Indeed, several studies have shown that *P. falciparum* EBA140 genotype variation correlates with the ability of this receptor to bind with human GPC ([@bib20], [@bib19]; [@bib16]), consistent with rapid coevolution of *GYPC* and its *P. falciparum* receptor. Under our proposed model, the evolutionary forces favoring the initial evolution of the GPC start codon remain unclear. It may have arisen by drift in a nonmalarial ancestral population or have been favored by unknown selective forces.

Because our data suggest that accelerated amino acid evolution is restricted to the human lineage, we believe *GYPC* evolution is not well explained by the "decoy" hypothesis. Decoy-driven positive selection at *GYPA* was hypothesized on the basis of high diversity within human populations coupled with high *ω* values in many primate lineages ([@bib2]). The broad phylogenetic distribution of rapid amino acid evolution at *GYPA* is potentially compatible with a generalized decoy function of Glycophorin A. In the case of human *GYPC*, rapid evolution mediated by interactions between GPC and *P. falciparum* EBA140, seems a more likely explanation for the observed evolutionary pattern.

Regardless of the specific evolutionary model invoked to explain the rapid evolution of *GYPC*, our results offer a possible contributing explanation to the observation that the virulence of *P. falciparum* is much higher in humans than other Apes ([@bib4]). Recently, it was shown that the ability of the *P. falciparum* receptor EBA175 to bind to Glycophorin A is altered by species-specific sialic acid modifications to the ligand ([@bib18]). Because of this, EBA175-mediated invasion of *P. falciparum* into *P. troglodytes* erythrocytes is greatly reduced. Our finding indicates that the GPC-dependent pathway (mediated by *P. falciparum* EBA140) is also not a possible route for *P. falciparum* invasion of the chimpanzee red blood cell.

*GYPC* Exhibits a Novel Mechanism of Protein Innovation
-------------------------------------------------------

One of our key findings is that human *GYPC* recently evolved the ability to encode GPC, while retaining the ability to encode GPD. Translation of multiple protein products from a single transcript through the use of differing start codons has been termed "leaky translation," a phenomenon that is known to affect many genes in diverse organisms ([@bib14]). The fact that GPC and GPD are products of leaky translation is well documented and likely is caused by the stronger Kozak motif associated with the GPD start codon, despite its downstream position relative to the GPC stop codon ([fig. 2](#fig2){ref-type="fig"}; [@bib15]). However, the evolutionarily derived status of this arrangement, and its restriction to humans, was not previously known.

Our study demonstrates that the evolution of human GPC occurred through co-option of 5′ UTR sequence by the protein-coding region of the gene. To our knowledge, this evolutionary pathway of protein diversification has not previously been documented. In fact, the pattern shown by *GYPC* suggests that leaky translation may be a general hallmark of recent protein innovation. Formation of a novel upstream codon can cause the expression of a new peptide while maintaining limited production of ancestral proteins. In some instances, leaky translation may represent a transient state as a gene shifts from encoding an ancestral to a derived protein. In other cases, selection may favor continued production of both proteins at the gene (mediated by maintenance of a stronger Kozak motif associated with downstream codons, for instance). It is unclear which of these cases applies to *GYPC* in humans. Regardless, we believe that the widespread occurrence of leaky translation among genes and organisms suggests that co-option of UTR sequence may represent a significant evolutionary pathway by which protein innovation occurs.

Conclusions
===========

*GYPC* has been subject to positive selection in the human lineage, leading to both extensive amino acid divergence from nonhuman primates and patterns of polymorphism consistent with a recent hitchhiking event. These data are consistent with selection for evasion of *P. falciparum* parasites subsequent to the evolution of a novel protein product (GPC) in humans. Beyond showing an interesting pattern of adaptive evolution, *GYPC* also demonstrates a novel mechanism by which protein diversity can evolve: capture of UTR sequence following the formation of a novel start codon. This process leads to leaky translation of proteins from multiple initiation sites. We suggest that leaky translation may be maintained when continued production of both proteins is beneficial or may represent an evolutionarily transient state as a gene shifts from encoding an ancestral to a novel derived protein. In either case, UTR capture offers a potential means by which major protein innovation can occur through mutation of only a single nucleotide site.
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